Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon‐Scanning Method

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical pharmacology and therapy

• Publication date

  2014-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/clpt.2013.226PMID 24398597PMCID PMC4689130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Table of Pharmacogenomic Biomarkers in Drug Labeling

  2015cited by this paper
• The US Preventive Services Task Force

  2015cited by this paper
• Guidelines for guideline developers: a systematic review of grading systems for medical tests

  2013cited by this paper
• Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

  2013cited by this paper
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

  2013cited by this paper
• ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

  2013cited by this paper
• Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies

  2013cited by this paper
• Technology-driven and evidence-based genomic analysis for integrated pediatric and prenatal genetics evaluation.

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

  2013cited by this paper
• ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing

  2013cited by this paper
• From the Cochrane Library

  2012cited by this paper
• Methodological quality of English-language genetic guidelines on hereditary breast-cancer screening and management: an evaluation using the AGREE instrument

  2012cited by this paper
• Pharmacogenomics Knowledge for Personalized Medicine

  2012cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing

  2012cited by this paper
• The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency

  2012cited by this paper
• ' s response to reviews Title : Methodological quality of English language genetic guidelines on hereditary breast cancer screening and management : an evaluation using the AGREE instrument

  2012cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing

  2012cited by this paper
• Do companion diagnostics make economic sense for drug developers?

  2012cited by this paper
• Deflating the Genomic Bubble

  2011cited by this paper
• Personalizing medicine with clinical pharmacogenetics

  2011cited by this paper
• Pharmacogenetics: From Bench to Byte— An Update of Guidelines

  2011cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy

  2011cited by this paper
• Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members

  2011cited by this paper
• NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

  2011cited by this paper
• Horizon scanning for new genomic tests

  2011cited by this paper
• CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

  2011influential reference
• An Introduction to Assessing Genomic Screening and Diagnostic Tests

  2011cited by this paper
• Summary of NICE guidance

  2011cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

  2011cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

  2011cited by this paper
• Clinical practice guidelines we can trust

  2011cited by this paper
• Genomics reaches the clinic: from basic discoveries to clinical impact.

  2011cited by this paper
• Evidence-based classification of recommendations on use of genomic tests in clinical practice: Dealing with insufficient evidence

  2010cited by this paper
• A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice

  2010cited by this paper
• Recommendations from the EGAPP Working Group: Genomic profiling to assess cardiovascular risk to improve cardiovascular health

  2010cited by this paper
• Development of the AGREE II, part 1: performance, usefulness and areas for improvement

  2010cited by this paper
• Development of the AGREE II, part 2: assessment of validity of items and tools to support application

  2010cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

  2009cited by this paper
• Update on the Methods of the U.S. Preventive Services Task Force: Insufficient Evidence

  2009cited by this paper
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

  2009cited by this paper
• Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

  2009cited by this paper
• ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.

  2009cited by this paper
• Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

  2009cited by this paper
• KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer.

  2009cited by this paper
• Can UGT1A1 Genotyping Reduce Morbidity and Mortality in Patients with Metastatic Colorectal Cancer Treated with Irinotecan

  2009cited by this paper
• ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy.

  2008cited by this paper
• A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

  2008cited by this paper
• Familial hypercholesterolaemia: summary of NICE guidance

  2008cited by this paper
• The evidence dilemma in genomic medicine.

  2008cited by this paper
• Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

  2008cited by this paper
• Pharmacogenetics: From Bench to Byte

  2008cited by this paper
• ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy.

  2007cited by this paper
• Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

  2007cited by this paper
• Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

  2007cited by this paper
• Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).

  2007cited by this paper
• ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities.

  2007cited by this paper
• IOM Roundtable on Evidence-Based Medicine

  2007cited by this paper
• The National Guideline Clearinghouse.

  2006cited by this paper
• 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COM BINATION TEMPLATE

  2005cited by this paper
• Evidence based? Caveat emptor!

  2005cited by this paper
• NATIONAL GUIDELINE CLEARINGHOUSE

  2005cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement

  2005cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement

  2005cited by this paper
• Searching for the Evidence Using PubMed

  2002cited by this paper
• Insufficient evidence.

  2001cited by this paper
• National guideline clearinghouse. URL: Www.guideline.gov/index.asp

  2000cited by this paper
• National guideline clearinghouse. URL: Www.guideline.gov/index.asp

  2000cited by this paper
• Genomics

  1998cited by this paper
• American College of Obstetricians and Gynecologists

  1979cited by this paper
• Hemoglobinopathies in pregnancy.

  1977cited by this paper
• Gynecologists

  1879cited by this paper
• Summary of recommendations: The Evaluation of Genomic

  year unknowncited by this paper
• Summary of Recommendations: The Evaluation of Genomic Applications

  year unknowncited by this paper

• Digital Transformation and Team-Based Care: Pharmacists in Multidisciplinary Models - A Narrative Review.

  2026cites this paper
• DNA-Based Population Screening for Adults.

  2026cites this paper
• From Genes to Public Health: The Journey Continues!

  2025cites this paper
• Young Women's Perspectives on Being Screened for Hereditary Breast and Ovarian Cancer Risk During Routine Primary Care.

  2024cites this paper
• Cost Effectiveness of Genomic Population Health Screening in Adults: A Review of Modeling Studies and Future Directions.

  2024cites this paper
• Population Genomic Screening for Three Common Hereditary Conditions

  2023cites this paper
• Implementing digital systems to facilitate genetic testing for hereditary cancer syndromes: An observational study of 4 clinical workflows.

  2023cites this paper
• Interpreting Incidentally Identified Variants in Genes Associated With Heritable Cardiovascular Disease: A Scientific Statement From the American Heart Association

  2023cites this paper
• Developing and assessing a kin keeping scale with application to identifying central influencers in African American family networks

  2023cites this paper
• Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment

  2023cites this paper
• Population Genomic Screening for Three Common Hereditary Conditions

  2023cites this paper
• Real-World Results from Combined Screening for Monogenic Genomic Health Risks and Reproductive Risks in 300 Adults

  2022cites this paper
• Nurses’ Knowledge, Attitudes, Confidence, and Practices with Genetics and Genomics: A Theory-Informed Integrative Review Protocol

  2022cites this paper
• Health equity in the implementation of genomics and precision medicine: A public health imperative.

  2022cites this paper
• Challenges and Opportunities for Communication about the Role of Genomics in Public Health

  2021cites this paper
• Actionable Variants Identified by Genome Sequencing: Penetrance and Outcomes at 1-year Following Return to Participants

  2021cites this paper
• From genes to public health: are we ready for DNA-based population screening?

  2021cites this paper
• Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives

  2021cites this paper
• A scoping review of social and behavioral science research to translate genomic discoveries into population health impact.

  2020cites this paper
• Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.

  2020cites this paper
• Strategic vision for improving human health at The Forefront of Genomics

  2020cites this paper
• Implementation of public health genomics and applications to public health dentistry.

  2020cites this paper
• Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines

  2019cites this paper
• Pharmacogenomics in clinical care.

  2019cites this paper
• Tracking human genes along the translational continuum

  2019cites this paper
• Moving the Needle on Action Around Evidence-Based Screening for Hereditary Conditions: Preparing State Chronic Disease Directors to Advance Precision Public Health

  2019cites this paper
• The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families

  2019cites this paper
• Ten years of Genome Medicine

  2019cites this paper
• Effective Identification of Lynch Syndrome in Gastroenterology Practice

  2019cites this paper
• A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health

  2018cites this paper
• Which Lynch syndrome screening programs could be implemented in the “real world”? A systematic review of economic evaluations

  2018cites this paper
• Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer

  2018influential citation
• Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee

  2018cites this paper
• Evaluating the role of public health in implementation of genomics-related recommendations: a case study in hereditary cancers using the CDC Science Impact Framework

  2018cites this paper
• HLBS-PopOmics: an online knowledge base to accelerate dissemination and implementation of research advances in population genomics to reduce the burden of heart, lung, blood, and sleep disorders

  2018cites this paper
• Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration.

  2018cites this paper
• Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program

  2018cites this paper
• Precision Genetic and Genomic Medicine in the Middle East and North Africa Region: Are We There Yet?

  2017cites this paper
• Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients

  2017cites this paper
• Genetic determinants of rare disorders and complex traits : insights into the genetics of dilated cardiomyopathy and blood cell traits

  2017cites this paper
• Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype‐Guided Antiplatelet Therapy

  2017cites this paper
• A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system

  2017cites this paper
• From public health genomics to precision public health: a 20-year journey

  2017cites this paper
• Precisely Where Are We Going? Charting the New Terrain of Precision Prevention.

  2017cites this paper
• A knowledge base for tracking the impact of genomics on population health

  2016cites this paper
• BRAT1 in Brain Function

  2016cites this paper
• CDC Grand Rounds: Family History and Genomics as Tools for Cancer Prevention and Control.

  2016cites this paper
• Early Diagnosis of HIV Infection in Infants - One Caribbean and Six Sub-Saharan African Countries, 2011-2015.

  2016cites this paper
• Gene-expression profiling of localized prostate cancer: still miles to go before we sleep.

  2016cites this paper
• Genomics in Public Health: Perspective from the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC)

  2015cites this paper
• A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit.

  2015cites this paper
• Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.

  2015cites this paper
• Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations

  2015cites this paper
• Utility before business

  2014cites this paper
• A Horizon‐Prioritizing Method Can Identify Gaps Among Genomic Application Guidelines

  2014cites this paper
• Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds

  2014cites this paper
• Personalized medicine in hematology — A landmark from bench to bed

  2014cites this paper
• What is translational genomics? An expanded research agenda for improving individual and population health

  2014cites this paper
• Risk Management and Healthcare Policy Dovepress the Human Genome Project, and Recent Advances in Personalized Genomics

  year unknowncites this paper